33.22

1.92% -0.65

After Hours: 33.26 0.04 +0.12%

Alkermes Plc (ALKS)

Overview News Price History Option Chain Financials Why ALKS Down? Discussions Forecast Stock Split

Alkermes Plc stock is traded at $33.22, with a volume of 1.63M. It is down -1.92% in the last 24 hours and up +19.67% over the past month. Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Previous Close:

$33.87

Open:

$33.92

24h Volume:

1.63M

Relative Volume:

0.69

Market Cap:

$5.52B

Revenue:

$1.48B

Net Income/Loss:

$241.66M

P/E Ratio:

23.19

EPS:

1.4325

Net Cash Flow:

$480.33M

1W Performance:

-4.46%

1M Performance:

+19.67%

6M Performance:

+3.07%

1Y Performance:

+18.90%

1-Day Range:

$32.96

$34.26

1-Week Range:

$32.76

$35.52

52-Week Range:

$25.16

$36.48

Alkermes Plc Stock (ALKS) Company Profile

Name

Alkermes Plc

Sector

Healthcare (1112)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

00-353-1-772-8000

Address

CONNAUGHT HOUSE, DUBLIN 4

Employee

2,050

Twitter

@alkermes

Next Earnings Date

2024-10-24

Latest SEC Filings

ALKS's Discussions on Twitter

Compare ALKS vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALKS Alkermes Plc	33.22	5.63B	1.48B	241.66M	480.33M	1.4325
TAK Takeda Pharmaceutical Co Adr	17.85	56.39B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	120.76	50.93B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.66	43.19B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.61	36.99B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	577.58	25.36B	3.18B	1.33B	1.04B	27.90

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Wolfe Research	Outperform
Nov-11-25	Initiated	Truist	Buy
Sep-26-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Sep-03-25	Initiated	Wells Fargo	Overweight
Jul-15-25	Initiated	Goldman	Buy
Jun-17-25	Upgrade	UBS	Neutral → Buy
May-28-25	Initiated	Needham	Buy
Mar-13-25	Initiated	RBC Capital Mkts	Sector Perform
Mar-04-25	Upgrade	UBS	Sell → Neutral
Feb-11-25	Initiated	Deutsche Bank	Buy
Nov-05-24	Upgrade	Stifel	Hold → Buy
Jun-17-24	Initiated	TD Cowen	Buy
Mar-19-24	Initiated	Robert W. Baird	Outperform
Feb-20-24	Downgrade	UBS	Neutral → Sell
Nov-20-23	Resumed	JP Morgan	Neutral
Oct-24-23	Upgrade	Evercore ISI	In-line → Outperform
Oct-17-23	Initiated	UBS	Neutral
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-16-22	Initiated	Piper Sandler	Neutral
Apr-22-22	Resumed	Goldman	Buy
Apr-20-22	Initiated	Goldman	Buy
Jan-27-22	Upgrade	Cantor Fitzgerald	Hold → Overweight
Dec-01-21	Initiated	Citigroup	Neutral
Oct-07-21	Upgrade	Jefferies	Hold → Buy
Sep-02-21	Downgrade	BofA Securities	Neutral → Underperform
Oct-15-20	Upgrade	Mizuho	Neutral → Buy
Jul-30-20	Downgrade	Goldman	Neutral → Sell
Feb-14-20	Downgrade	BofA/Merrill	Buy → Neutral
Feb-14-20	Reiterated	H.C. Wainwright	Neutral
Feb-14-20	Downgrade	JP Morgan	Overweight → Neutral
Feb-06-20	Initiated	Mizuho	Neutral
Jan-31-20	Upgrade	Wolfe Research	Underperform → Peer Perform
Sep-05-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jul-15-19	Upgrade	Goldman	Sell → Neutral
May-31-19	Initiated	H.C. Wainwright	Neutral
May-01-19	Downgrade	Citigroup	Buy → Neutral
Dec-19-18	Downgrade	Goldman	Neutral → Sell
Dec-14-18	Initiated	Wolfe Research	Underperform
Dec-13-18	Downgrade	Credit Suisse	Outperform → Underperform
Nov-05-18	Initiated	Piper Jaffray	Neutral
Aug-07-18	Initiated	Stifel	Hold
Jun-21-18	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jun-06-18	Initiated	B. Riley FBR, Inc.	Buy
May-16-18	Upgrade	Citigroup	Neutral → Buy
May-11-18	Initiated	BofA/Merrill	Buy

View All

Alkermes Plc Stock (ALKS) Latest News

Apr 14, 2026

Alkermes (ALKS) nears 52-week high on increasing orexin receptor market interest - MSN

Apr 14, 2026

Alkermes (ALKS) Reveals Positive Findings on Lybalvi for Schizop - GuruFocus

Apr 14, 2026

Alkermes publishes 56-week study on Lybalvi negative symptoms By Investing.com - Investing.com Australia

Apr 14, 2026

Alkermes publishes 56-week study on Lybalvi negative symptoms - Investing.com

Apr 14, 2026

Schizophrenia study tracks symptom gains for 56 weeks on LYBALVI - Stock Titan

Apr 14, 2026

Apr 13, 2026

Should Alkermes’ (ALKS) New Phase 3 Narcolepsy Program Reshape Its Sleep-Disorder Investment Narrative? - simplywall.st

Apr 13, 2026

Alkermes (ALKS) director Nancy Lurker exercises RSUs, netting 13,555 shares - Stock Titan

Apr 13, 2026

Apr 11, 2026

ALKS (Alkermes) Cash Receipts from Operating Activities - GuruFocus

Apr 11, 2026

Apr 10, 2026